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Tacrolimus is a calcineurin inhibitor frequently used in transplanta­
tion to prevent allograft rejection.[1,2] Its use has been associated 
with improved graft survival, and it currently forms the cornerstone 
of immunosuppressive therapy in solid­organ transplantation. [3] 
There is a shortage of donors, especially cadaveric donors, on 
an international and local level. Maintaining graft function is 
therefore of the utmost importance to protect a limited resource 
in medicine.[4,5]
Tacrolimus has a narrow therapeutic window and wide 
pharmacokinetic variability in transplant recipients.[1,6,7] In clinical 
practice, this translates into marked inter­ and intra­patient variability 
(IPV) in measured tacrolimus predose trough concentrations (C0), 
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Background. Tacrolimus forms the cornerstone for immunosuppression in solid­organ transplantation. It has a narrow therapeutic window 
with wide inter­ and intra­patient variability (IPV). Cytochrome P­450 3A5 (CYP3A5) is the main enzyme involved in tacrolimus metabolism, 
and rs776746A>G is the most frequently studied polymorphism in the CYP3A5 gene. The rs776746A>G (i.e. CYP3A5*3) single­nucleotide 
polymorphism in CYP3A5 alters tacrolimus predose trough concentration (C0) and may also affect IPV, which may lead to immune­ and/or 
drug­mediated allograft injury. CYP3A5*3 may result in absent (*3/*3), partial (*1/*3) or normal (*1/*1) CYP3A5 expression. The effect of 
CYP3A5*3 on tacrolimus exposure and variability has not been examined in South African (SA) transplant recipients.
Objectives. To determine the frequencies and effect of CYP3A5 and adenosine triphosphate­binding cassette subfamily B member 1 
(ABCB1) polymorphisms on tacrolimus C0/dose ratios in different ethnic groups attending a tertiary renal transplant clinic in SA, and other 
factors that may explain inter­ and IPV in tacrolimus C0.
Methods. All consenting stable renal transplant recipients on tacrolimus at the Livingstone Hospital Renal Unit in Port Elizabeth, SA, were 
included. Tacrolimus concentrations were obtained using a microparticle enzyme immunoassay method (ARCHITECT analyser, Abbott 
Laboratories). Polymerase chain reaction/restriction fragment length polymorphism was used to genotype for CYP3A5*3 and *6 allelic variants.
Results. There were 43 participants (35% black African, 44% mixed ancestry and 21% white), with a mean age of 44.5 years, median 
duration post­transplant of 47 months and median (interquartile range) creatinine and estimated glomerular filtration rate levels of 
118 (92 ­ 140) µmol/L and 62 (49 ­ 76) mL/min at study inclusion. The mean tacrolimus C0 in the study was 6.7 ng/mL, with no difference 
across the different ethnic groups. However, the mean total daily dose of tacrolimus required was 9.1 mg (0.12 mg/kg), 7.2 mg (0.09 mg/kg) 
and 4.3 mg (0.06 mg/kg) in black, mixed­ancestry and white patients, respectively (p=0.017). The frequencies for CYP3A5 expressors (i.e. 
CYP3A5*1/*1 + CYP3A5*1/*3 genotypes) were 72%, 100%, 76% and 12% for all patients combined and black, mixed­ancestry and white 
patients, respectively. The frequencies for CYP3A5 non­expressors (i.e. CYP3A5*3/*3 genotypes) were 0%, 24% and 88% among the black, 
mixed­ancestry and white patients, respectively. None of the patients carried the CYP3A5*6 allele. CYP3A5*1/*1 and CYP3A5*1/*3 genotype 
carriers required a two­fold increase in dose compared with the non­expressor genotype carriers, CYP3A5*3/*3 (p<0.05). CYP3A5*3/*3 
carriers also demonstrated higher IPV than CYP3A5*1/*1 and *1/*3 carriers (18.1% v. 14.2%; p=0.125).
Conclusions. Compared with global transplant populations, SA renal transplant recipients demonstrated a very high rate of CYP3A5 
expression, with a significant impact on tacrolimus pharmacokinetics. Genetic variation in CYP3A5 expression affects tacrolimus dosing 
requirements, and knowing the CYP3A5 genotype of transplant patients may allow better dose prediction compared with current standard 
dosing recommendations in a multi­ethnic population. Overall, black African patients required higher doses of tacrolimus than their white 
counterparts. While further prospective studies are needed to better evaluate dosing algorithms, it would appear that the starting dose of 
tacrolimus should be higher in black and mixed­race patients.
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which makes selection of the appropriate dose difficult for transplant 
physicians.[1] Tacrolimus IPV, which is defined as fluctuations of 
measured tacrolimus C0 in an individual over a given period of time, 
is an independent predictor for worsening graft function.[8,9] Variability 
in tacrolimus C0 may result in subtherapeutic levels, leading to inferior 
graft outcomes from immune­mediated allograft injury with allograft 
rejection.[10] On the other hand, high tacrolimus C0 may also lead to an 
adverse side­effect profile and renal toxicity.[11,12]
While various non­pharmacogenetic factors such as poor 
adherence, high­fat meals, grapefruit intake, drug­drug interactions 
and circadian rhythms may explain some of this variability,[1,13] much 
attention has been given in the past two decades to pharmacogenomics 
and the cytochrome pathway.[14] Tacrolimus is predominantly a 
substrate for metabolism by cytochrome P­450 3A5 (CYP3A5) and is 
dependent on cellular transport by P­glycoprotein (P­gp), coded for 
by the adenosine triphosphate (ATP)­binding cassette subfamily B 
member 1 (ABCB1) gene. Single­nucleotide polymorphisms (SNPs) 
in the CYP3A5, CYP3A4 and ABCB1 genes affect tacrolimus C0 and 
the dose required through variability in metabolism and absorption, 
respectively.[15,16]
The CYP450 enzymes are membrane­bound proteins found in the 
endoplasmic reticulum that facilitate metabolism of a wide variety of 
drugs.[1] CYP3A5 is the major enzyme involved in the metabolism of 
tacrolimus, while CYP3A4 plays a minor role.[17,18] The rs776746A>G 
(i.e. CYP3A5*3) SNP in CYP3A5 abolishes CYP3A5 enzyme activity 
and has been reported to alter tacrolimus C0. CYP3A5 may result 
in absent (*3/*3), partial (*1/*3) or normal (*1/*1) CYP3A5 expres­
sion. [15­17] A second allele (CYP3A5*6) resulting from a splicing variant 
at 14690G>A also produces a non­functional CYP3A5 enzyme.[1,18]
Transplant recipients with normal or partial expression of 
CYP3A5 require higher tacrolimus doses than non­expressors to 
achieve similar therapeutic tacrolimus C0.[15,17,19] Other enzymes may 
also influence inter­ and IPV in tacrolimus dosing, namely P450 
oxidoreductase (POR), nuclear receptor perioxisome proliferator­
activated receptor alpha (PPAR­α) and CYP2C8.[1,19]
The ABCB1 gene encodes P­gp, which functions as an ATP­
dependent efflux pump that protects intestinal cells from harmful 
substances. The absorption of certain drugs from the gut is therefore 
inversely proportional to P­gp expression. Polymorphisms in ABCB1 
alter expression of P­gp, which in turn can affect tacrolimus C0 by 
altering drug absorption from the intestine. An SNP in exon 26 (3435 
C>T) in the ABCB1 gene has been widely studied for its effects on 
many drugs.[1,16,20] The ABCB1 3435T allele is associated with reduced 
expression of ABCB1.[20,21] The role of SNPs in ABCB1 on tacrolimus 
C0 and dosing is currently controversial, and several studies have 
shown conflicting results pointing towards a minor role.[15,19,22]
Objectives
The frequencies of SNPs of CYP3A5 and ABCB1 and their effect 
on tacrolimus C0/dose ratios have been described internationally, 
but not in South African (SA) renal transplant recipients.[15,23­25] 
We therefore set out to determine the frequencies and effect of 
CYP3A5 and ABCB1 polymorphisms on tacrolimus C0/dose ratios 
in different ethnic groups attending a tertiary renal transplant clinic 
at Livingstone Hospital, Port Elizabeth, SA, and to determine other 
factors that may explain inter­ and IPV in tacrolimus C0.
Methods
Study participants and sample collection
A cohort of stable renal transplant recipients at least 12 months post 
transplant was invited to participate in the study. Stable was defined 
as having had no major intercurrent illness during the preceding 
12 months. Ethics approval for genetic testing was obtained from 
the Walter Sisulu University Ethics Committee (ref. no. 017/2016). 
The study was a retrospective cohort study, and information was 
obtained from four quarterly periods prior to the inclusion date. 
Data were collected on relevant demographic and clinical measures. 
Self­reported ethnicity was included in our data collection tool and 
categorised as black African, mixed ancestry and white.
All consenting patients aged >18 years who were using tacrolimus 
as part of their immunosuppression were included. Five millilitres of 
venous whole blood was taken in ethylenediaminetetra­acetic acid­
containing blood tubes and stored at –20oC. Repeated tacrolimus 
C0 and dosages were obtained retrospectively from case notes. Data 
collected included body weight, age, level of education, type of 
immunosuppression used, perceived medication adherence, type of 
transplant, months post­transplant, ethnicity (self­reported) and the 
aetiology of chronic kidney disease. Five recipients who were positive 
for HIV were excluded from the study because of potential drug 
interactions. Two other patients were excluded because they were also 
using medications known to affect tacrolimus C0, such as antifungal 
agents, rifampicin, verapamil, macrolide antibiotics and antiepileptics.
Analytical methods
Tacrolimus C0 (ng/mL) was obtained by means of a microparticle 
enzyme immunoassay method using the ARCHITECT analyser 
(Abbott Laboratories, USA). DNA was extracted using the QIAamp 
DNA Mini Kit (Qiagen, Germany), following the manufacturer’s 
instructions. Polymerase chain reaction (PCR)­restriction fragment 
length polymorphism (RFLP) was used to genotype CYP3A5*3 
and *6 and ABCB1. Each PCR reaction contained the following 
reagents: 0.40 μM of each of the forward and reverse primers 
(Inqaba Biotechnical Industries, SA), 100 ng of genomic DNA, 
1  × Green GoTaq Flexi Reaction Buffer (Promega, USA), 0.2 mM 
deoxyribonucleotide triphosphate (Promega), 2.5 mM magnesium 
chloride (Promega) and 0.5 U GoTaq Flexi DNA Polymerase 
(Promega), and was made up to a volume of 25 μL with sterile 
deionised water.
PCR and RFLP conditions are summarised in Table 1.
Statistical analysis
Categorical variables were summarised as frequencies and 
percentages. Continuous variables were summarised as means and 
standard deviations (SDs). Student’s t­test or analysis of variance 
was used to compare continuous tacrolimus measures (dosage, level 
and C0 dose/kg) variables between two groups and three groups, 
respectively. Linear mixed­effects models were used to analyse the 
change in repeated variables (tacrolimus dose, C0/dose, creatinine 
and estimated glomerular filtration rate (eGFR)) associated with 
increasing time. IPV in tacrolimus was expressed as a coefficient of 
variation using the following formula: CV% = (σ/μ) × 100
A p­value <0.05 was considered statistically significant. Statistical 
analysis was carried out using Stata statistical software, version 15.1 
(StataCorp, USA).
Results
Study participants
There were 43 study participants, of whom 18 (42%) received a 
kidney from a related living donor, with the rest receiving cadaveric 
transplants. All the patients were stable during the study period with 
no major illnesses reported. Baseline demographics and clinical 
characteristics are shown in Table 2. All the participants were non­
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smokers. Self­reported ethnic groups were black African (n=15), 
mixed ancestry (n=19) and white (n=9).
New­onset diabetes after transplantation (NODAT) was more 
common in males, with a prevalence of 10/13 (77%) v. 23% in females. 
Patients with NODAT had a higher mean serum creatinine level than 
those without NODAT (132 µmol/L v. 117 µmol/L; p=0.253) and 
were more likely to have autosomal dominant polycystic kidney 
disease (ADPKD), with NODAT developing in 67% of those with 
ADPKD v. 24% of the others.
Indication for transplantation
Hypertension (54%) was the leading indication for transplantation, 
followed by ADPKD (14%), glomerulonephritis (12%) and congenital 
abnormalities of the kidney and urinary tract (9%). Other causes 
included acute tubular necrosis, urological strictures and unknown 
aetiologies.
Tacrolimus dose and C0 over the study period
Table 3 shows the mean tacrolimus C0 and dosing requirements 
during the study period. Mean tacrolimus C0 (6.7 ng/mL) and dose 
(7.3 mg/d) did not change significantly over the study period. The 
mean (SD) creatinine level was 121.5 (39) µmol/L, with an absolute 
increase over the study period of 8.9 µmol/L (p=0.004). The mean 
(SD) eGFR was 62 (18) mL/min/1.72 m2 and remained unchanged 
over the study period (p=0.616).
Table 4 shows the frequency and distribution of genotypes across 
ethnic groups. Among those who could be genotyped (39 of the 
43 participants), homozygous CYP3A5*1/*1 frequency was highest 
in black Africans (64%), followed by patients of mixed ancestry 
(41%), while the genotype was not observed among white patients; 
the inverse was true for the non­expressor CYP3A5*3/*3 genotype, 
with frequencies of 0%, 24% and 88% among black Africans, patients 
of mixed ancestry and whites, respectively. Overall, 72% of the 
study population were CYP3A5 expressors (CYP3A5*1/*1 + *1/*3). 
CYP3A5*6 was not observed in the study population.
The ABCB1 3435C>T SNP genotypes also showed differences 
among the different race groups, with the exception that the T/T 
genotype appeared less frequently in black Africans (0%) than in 
patients of mixed ancestry (11%) and whites (33%). Two participants 
could not have the ABCB1 gene typed.
Effect of ethnicity on tacrolimus C0 and dose
The mean (SD) tacrolimus dose for each ethnic group was as 
follows: black African 9.1 (4.2) mg, mixed ancestry 7.2 (4.1) mg, 
and white 4.3 (2.2) mg (Table 5). This translates into a weight­based 
Table 1. List of primers and polymerase chain reaction cycling conditions for mutation detection
SNP Primer (5′ - 3′) Ta, ext Thermal cycling conditions Restriction enzyme
CYP3A5*3 F: CATCAGTTAGTAGACAGATGA
R: GGTCCAAACAGGGAAGAAATA
51oC, 30 s 94oC, 3 min
94oC, 30 s
51 oC, 30 s
72 oC, 30 s
72oC, 10 min
SspI,
12 ­ 16 h
CYP3A5*6 F: GTGGGGTGTTGAZAGCTAAAG
R: TGGAAGATGATTCAGCAGATAGT
55oC, 30 s 94oC, 3 min
94oC, 30 s
55 oC, 30 s
72 oC, 1 min
72oC, 10 min
DdeI,
12 ­ 16 h
ABCB1 (1236 C>T) F: ACTCTTGTTTTCAGCTGCTTG
R: GAGTCACTGCCTAATGTAAGTCTCT
54oC, 30 s 94oC, 3 min
94oC,30 s
54 oC, 30 s
72 oC, 50 s
72oC, 10 min
MboI,
12 ­ 16 h
SNP = single­nucleotide polymorphism; CYP3A5 = cytochrome P­450 3A5 gene; ABCB1 = adenosine triphosphate­binding cassette subfamily B member 1 gene; F = forward primer;  
R = reverse primer; Ta = annealing temperature; ext = extension time.
Table 2. Baseline demographics and clinical characteristics 
of the population studied (N=43)
Characteristic
Age (years), mean (SD) 45 (12)
Males, n (%) 25 (58)
Cadaveric transplants, n (%) 25 (58)
Living related donor transplants, n (%) 18 (42)
Months post transplant, median (IQR) 47 (24 ­ 110)
Indication for transplant, n (%)
Hypertension 23 (54)
ADPKD 6 (14)
Glomerulonephritis 5 (12)
CAKUT 4 (9)
Diabetic nephropathy 1 (2)
Other* 4 (9)
Weight (kg), mean (SD) 75 (14)
Ethnicity, n (%)
Black African 15 (35)
Mixed ancestry 19 (44)
White 9 (21)
HIV status negative, n (%) 43 (100)
Baseline immunosuppression, n (%)
Prednisone 43 (100)
Azathioprine 10 (23)
MMF 30 (70)
Tacrolimus 43 (100)
NODAT, n (%) 13 (30)
Males 10 (77)
Females 3 (23)
SD = standard deviation; IQR = interquartile range; ADPKD = autosomal dominant 
polycystic kidney disease; CAKUT = congenital abnormalities of the kidney and urinary 
tract; MMF = mycophenolate mofetil; NODAT = new­onset diabetes after transplantation.
*Includes acute tubular necrosis, urological strictures and unknown causes.
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dose for black, mixed­ancestry and white study participants of 
0.12, 0.09 and 0.06 mg/kg, respectively, which differed significantly 
between ethnic groups (p=0.017). Overall, there was no significant 
change in tacrolimus C0 over time when observed in each ethnic 
group.
Effect of genotype on tacrolimus C0
Table 6 shows the effect of CYP3A5 and ABCB1 SNPs on tacrolimus 
C0 over the four quarters during the study period. Overall, there was 
no significant change in tacrolimus C0 over time when analysed per 
genotype.
Table 3. Patient pharmacokinetic and clinical characteristics during the study period, by quarter
Characteristic Q1 Q2 Q3 Q4 Mean Coefficient 95% CI p-value*
Tacro dose (mg/d), mean (SD) 7.2 (4.2) 7.3 (4.2) 7.3 (4.2) 7.3 (4.2) 7.3 (4.1) –0.028 –0.068 ­ 0.0126 0.177
Tacro C0 (ng/mL), mean (SD) 6.6 (1.4) 6.7 (1.5) 6.5(1.5) 6.9 (1.7) 6.7(1.2) –0.057 –0.209 ­ 0.094 0.459
Tacro C0/dose (ng.mL­1/mg) 0.92 0.92 0.89 0.95 0.92
Tacro C0/dose (ng.mL­1/mg.kg­1) (SD) 98 (68) 99 (77) 96 (75) 106 (86) 100 (75) –2.281 –5.192 ­ 0.6300 0.125
Creatinine (µmol/L), median (IQR) 117.8 
(35.4)
119.7 
(35.9)
122.7 
(40.5)
126.7  
(51.5)
121.51 
(39.0)
–3.082 –5.200 ­ –0.964 0.004
eGFR (mL/min/1.72 m2), median 
(IQR)
62 (18) 62 (22) 62 (19) 60 (189) 62 (18) 0.266 –0.775 ­ 1.308 0.616
Q = quarter; Tacro = tacrolimus; CI = confidence interval; SD = standard deviation; C0 = predose trough concentration; IQR = interquartile range; eGFR = estimated glomerular filtration rate.
*p<0.05 indicates significant change in repeated measures over time.
Table 4. Frequency and distribution of genotypes across ethnic groups
Genotype Total (N=43) Black African (N=15) Mixed ancestry (N=19) White (N=9)
CYP3A5, n (%)*
*1/*1 (AA) 16 (41) 9 (64) 7 (41) 0
*1/*3 (AG) 12 (31) 5 (36) 6 (35) 1 (12)
*3/*3 (GG) 11 (28) 0 4 (24) 7 (88)
N/R 4 1 2 1
ABCB1, n (%)*
C/C 23 (56) 10 (71) 9 (50) 4 (44)
C/T 13 (32) 4 (29) 7 (39) 2 (22)
T/T 5 (12) 0 2 (11) 3 (33)
N/R 2 1 1 0
CYP3A5 = cytochrome P­450 3A5 gene; ABCB1 = adenosine triphosphate­binding cassette subfamily B member 1 gene; N/R = no result.
*CYP3A5 and ABCB1 carrier frequency was determined only for those patients who could be genotyped.
Table 5. Effect of ethnicity on tacrolimus C0 and dose
Clinical characteristics Race Q1 Q2 Q3 Q4 p-value Mean (SD)
Tacrolimus dose (mg), mean (SD) Black African 8.9 (3.6) 9.2 (4.2) 9.2 (4.2) 9.2 (4.2) 0.171 9.1 (4.1)
Mixed ancestry 7.2 (4.1) 7.2 (4.1) 7.2 (4.1) 7.2 (4.1) * 7.2 (4.1)
White 4.3 (2.2) 4.3 (2.2) 4.3 (2.2) 4.3 (2.2) * 4.3 (2.2)
p­value 0.017 0.017 0.017 0.016 0.017
Tacrolimus C0 (ng/mL), mean (SD) Black African 7.0 (1.8) 6.8 (1.6) 7.1 (1.4) 6.8 (1.5) 0.998 6.9 (1.6)
Mixed ancestry 6.7 (1.5) 6.3 (1.5) 6.5 (1.6) 6.5 (1.4) 0.708 6.5 (1.5)
White 7.1 (2.2) 6.1 (1.3) 6.1 (1.6) 6.4 (1.3) 0.376 6.5 (1.6)
p­value 0.890 0.524 0.300 0.770 0.519
C0 = predose trough concentration; Q = quarter; SD = standard deviation.
*Statistical testing not justified owing to lack of change in repeated measures over time.
Table 6. Effects of polymorphisms in CYP3A5 and ABCB1 on tacrolimus C0
Genotype Allelic status
Tacrolimus C0 (ng/mL), mean (SD)
p-valueQ1 Q2 Q3 Q4 Mean
CYP3A5*1/*1 A/A 6.3 (0.8) 6.5 (1.7) 6.5 (1.7) 6.53 (1.5) 6.5 (1.3) 0.783
CYP3A5*1/*3 G/A 7.0 (1.5) 6.8 (1.6) 6.5 (1.2) 7.3 (2.1) 6.9 (1.6) 0.669
CYP3A5*3/*3 G/G 6.2 (1.2) 6.3 (1.4) 6.2 (1.3) 6.7 (1.4) 6.4 (1.3) 0.263
ABCB1 C/C 6.5 (1.1) 6.5 (1.4) 6.6 (1.6) 7.0 (1.7) 6.7 (1.4) 0.181
C/T 6.6 (1.6) 6.6 (1.3) 5.9 (1.1) 6.9 (1.9) 6.5 (1.5) 0.877
T/T 7.5 (2.0) 7.7 (2.7) 7.3 (1.6) 6.7 (1.6) 7.3 (2.0) 0.297
C0 = predose trough concentration; Q = quarter; CYP3A5 = cytochrome P­450 3A5 gene; ABCB1 = adenosine triphosphate­binding cassette subfamily B member 1 gene.
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Effect of genotype on tacrolimus dose requirements
The distribution of CYP3A5 expressor status (i.e. CYP3A5*1/*1 + *1/*3) 
in patients who could be genotyped was 100%, 75% and 12.5% among 
black African, mixed­ancestry and white participants, respectively. 
CYP3A5*1/*1 and CYP3A5*1/*3 genotypes were associated with a two­
fold increase in required tacrolimus dose (p<0.05). The mean (SD) total 
daily dose per genotype was 9 (0.12) mg/kg, 5 (0.07) mg/kg and 3 (0.04) 
mg/kg for CYP3A5*1/*1, *1/*3 and *3/*3, respectively.
CYP3A5 genotypes had mean (SD) C0/dose ratios of 54 (16), 95 (57) 
and 170 (94) for CYP3A5*1/*1, *1/*3 and *3/*3, respectively (p<0.001). 
The C0/dose ratio per CYP3A5 genotype over time can be seen in 
Fig. 1. ABCB1 genotypes had the following C0/dose ratios (mean (SD)): 
78 (53) for C/C, 142 (104) for C/T and 103 (66) for T/T (p=0.015 for 
C/C v. C/T and p=0.347 for C/C v. T/T). The mean (SD) total daily dose 
per ABCB1 genotype was 6 (0.09) mg/kg, 3 (0.05) mg/kg and 5 (0.07) 
mg/kg for C/C, C/T and T/T, respectively.
Fig. 1 demonstrates the C0/dose for tacrolimus by genotype during 
the study period, while Figs 2 and 3 demonstrate the effect of CYP3A5 
and ABCB1 genotype on tacrolimus C0/dose ratios per participant, 
respectively.
IPV during the study period
Tacrolimus C0 varied among individual transplant recipients. Fig. 4 
shows tacrolimus levels for each individual in the cohort over the 
four study quarters.
Fig. 5 shows the distribution of tacrolimus IPV in the study cohort 
during the study period. Figs 6 and 7 show IPV by genotype and 
ethnicity, respectively. IPV was divided into two groups using the 
median (interquartile range) IPV of 14.4% (10.5  ­ 19.0) as a cut­
Figure 1.The eﬀect of CYP3A5 on Co/Dose concentration during study period 
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Fig. 1. Effect of CYP3A5 on C0/dose ratio during study period. (CYP3A5 = 
cytochrome P-450 3A5 gene; C0 = predose trough concentration; Q = 
quarter.)
Figure 2.Effect of CYP3A5 on tacrolimus Co/dose ratio in study population 
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Fig. 2. Effect of CYP3A5 on tacrolimus C0/dose ratio in the study population. 
(CYP3A5 = cytochrome P-450 3A5 gene; C0 = predose trough concentration.)
 
Figure 3. Effect of ABCB1 on tacrolimus C0/dose ratio 
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Fig. 3. Effect of ABCB1 on tacrolimus C0/dose ratio. (ABCB1 = ATP-binding 
cassette subfamily B member 1 gene; C0 = predose trough concentration.) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Tacrolimus C0 levels per patient over the study period 
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Fig. 4. Tacrolimus C0 per patient over the study period. (C0 = predose trough 
concentration; Q = quarter.)
Figure 5. Tacrolimus IPV amongst participants during study period (n=39). The median (14.4%) is 
shown by the dotted line. 
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Fig. 5. Tacrolimus IPV among study participants over the study period 
(N=39). The median (14.4%) is shown by the dotted line. (IPV = intra-
patient variability.)
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off. IPV ≥14.4% was classified as high and <14.4% as low. CYP3A5 
expressors (*1/*1 + *1/*3, n=28) had a lower IPV than CYP3A5 
non­expressors (*3/*3, n=11) with a mean (SD) IPV of 14.2% (6.6) 
v. 18.1% (7.5), respectively (p=0.125). Similarly, white participants 
had a higher IPV than those of black African and mixed ancestry 
(p=0.041). Creatinine did not differ between high­ and low­IPV 
groups (p=0.757).
Discussion
This was an observational study examining tacrolimus C0 in stable 
renal transplant recipients attending a transplant clinic in Port 
Elizabeth, SA. Patients in the immediate post­transplant period were 
excluded because variations in tacrolimus levels often occur due to 
drug interactions such as high prednisone exposure, fluid shifts, and 
individual physician preferences to obtain therapeutic C0.[9]
Over time, the mean tacrolimus C0 and dose did not change among 
the different genotypes studied. There was a slight rise in serum 
creatinine over the study period, but eGFR remained unchanged.
In this cohort, CYP3A5 expression varied markedly by ethnic 
group. Black African participants were much more likely to be 
CYP3A5*1/*1 and *1/*3 carriers reflecting full or partial expression 
of CYP3A5 compared with white participants. Conversely, no black 
African participant was a CYP3A5 non­expressor (CYP3A5*3/*3), 
while 88% of white participants were homozygous CYP3A5 non­
expressors, with none having normal expression of CYP3A5. Black 
African participants required a 2.1­fold higher dose to maintain 
therapeutic tacrolimus C0 compared with white participants. This 
is consistent with a previous study by Macphee et al.[14] Previous 
studies have also shown that white patients were more likely than 
black patients to present with CYP3A5*3/*3 genotypes.[24,25] Haufroid 
et al.[23] also demonstrated an allele effect of CYP3A5*1/*1, with a 
2.3­fold increase in daily dose requirements to maintain therapeutic 
tacrolimus C0 compared with CYP3A5*3/*3.
The dose of tacrolimus required to achieve similar tacrolimus 
C0 was clearly affected by CYP3A5 genotype. Participants with the 
CYP3A5*3/*3 non­expressor genotype achieved over three times the 
tacrolimus C0/dose ratio compared with those with normal expression 
(CYP3A5*1/*1). Similarly, participants with the CYP3A5*1/*1 genotype 
required a twofold increase in tacrolimus dose compared with those 
with the CYP3A5*3/*3 genotype in order to maintain therapeutic 
tacrolimus C0. This finding has major economic implications for SA, 
where until recently no cheaper generic formulations of tacrolimus 
have been available and where tacrolimus drug costs form a substantial 
part of the cost of transplantation.[4,26]
Participants of mixed ancestry had more variable expression of 
CYP3A5 than black Africans or whites. Black African and white 
ethnicity therefore appear to be a good proxy for CYP3A5 expression 
and non­expression, respectively, and could potentially allow 
reasonable prediction of dosing requirements in these population 
groups, while CYP3A5 genotyping could be reserved for patients of 
mixed ancestry, among whom there is a much wider spread in enzyme 
expression. Accurate prediction of dosing through this combination 
of ethnic profiling and genotyping could both be cost­effective and 
lead to improved graft outcomes by rapidly achieving appropriate 
tacrolimus C0, although further prospective studies would be needed 
to confirm this. In a recently published randomised controlled trial of 
pharmacogenetic adaptation of the tacrolimus starting dose according 
to CYP3A5 expression, genotyping did not lead to a higher percentage 
of participants reaching the desired outcome compared with the 
standard weight­based dose, and did not improve clinical outcomes. [25] 
However, the ethnic distribution in that study was markedly skewed 
towards white patients (78%), among whom non­expressor status is 
much more common and likely to lessen the effect of pharmacogenetic 
adaptation. In our cohort, 72% of participants were CYP3A5 expressors 
or partial expressors. In another study, CYP3A5*1/*1 genotype carriers 
were found to have more rejection episodes than heterozygous carriers 
(CYP3A5*1/*3) and homozygous non­expressor genotype carriers 
(CYP3A5*3/*3).[27] Studies with a more equal ethnic distribution are 
needed to further assess genotype­based dosing. Similar studies by 
Thervet et al.[28] and Shuker et al.[25] showed that genotype­based 
dosing was associated with fewer dose modifications and a shorter time 
to reach the target tacrolimus C0. However, genotype­based dosing did 
not improve clinical outcomes.[25,28]
Black African participants predominantly expressed the ABCB1 
C/C and C/T genotypes, with no expression of the T/T genotype. 
However, overall expression of the ABCB1 genotype was more evenly 
distributed among the different ethnic groups than that of CYP3A5, 
and there was no clear polarising effect of ethnicity on ABCB1 
expression. There was a decrease in the achieved tacrolimus C0/dose 
ratio among participants carrying the C/C genotype compared with 
C/T and T/T. This is probably due to increased expression of P­gp, 
which reduces net absorption of tacrolimus at the intestinal level. 
These findings are also consistent with those of Helal et al.,[21] who 
demonstrated that participants expressing the C/C genotype had 
a lower tacrolimus C0/dose ratio compared with other genotypes 
of ABCB1. Previous studies have not consistently demonstrated an 
effect of the ABCB1 SNP on tacrolimus C0/dosing.
Variability of tacrolimus C0 strongly correlates with a negative effect 
on graft outcomes.[9,10] Studies have shown that a tacrolimus SD of C0 
of >2 is associated with increased late acute rejection, and that patients 
with higher IPV have a 1.4 times increased risk of allograft injury or 
rejection.[29] High variability in tacrolimus C0 has also been shown to 
correlate with poorer overall graft function. [10,13,29,30] Although most of 
our study participants had therapeutic tacrolimus C0, significant intra­ 
and IPV was present in 14.4% (see Fig. 6). This is somewhat lower 
than the figure reported by Shuker et al.[13] in their large study of 808 
renal transplant recipients, in which the median IPV was 16.2%, and 
may reflect the high proportion of CYP3A5 expressors in our study 
(72%). In an excellent review of the subject,[13] these authors noted that 
CYP3A5 non­expression was associated with increased tacrolimus 
IPV in one small Korean study where the expressor genotype was 
present in 55% of the cohort,[31] but not in three larger studies,[29,32,33] 
where the prevalence of the CYP3A5 expressor genotype in the 
population studied was very much lower at between 9% and 45%. 
Similar to the Korean study, the prevalence of the CYP3A5 expressor 
genotype in our cohort was much higher at 72% and is comparable to 
the previously reported allele frequency of 85% in healthy SA black 
Africans.[34] The increase in IPV of tacrolimus C0 in CYP3A5 non­
expressors has been postulated to be due to their increased reliance 
on CYP3A4 for tacrolimus metabolism and the fact that CYP3A4 
is more prone to induction and inhibition. [35] Similarly, CYP3A5 
non­expressors were shown to be more prone to the inhibitory 
effects of fluconazole on tacrolimus metabolism owing to the fact 
that fluconazole relies predominantly on CYP3A4 for metabolism. [36] 
Knowing the CYP3A5 expressor status of an individual therefore also 
has relevance in determining the risk of drug­drug interactions in 
transplant recipients, who not infrequently require treatment with 
drugs that interfere with CYP450 metabolism.
CYP3A5 SNPs only explain 40 ­ 50% of tacrolimus variability 
among patients.[1] Other factors such as food ingestion, type of assay 
used, diarrhoea, drug­drug interactions, haematocrit and compliance 
issues may also play a role.[13,24] Non­adherence to tacrolimus is 
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probably the most common reason for tacrolimus inter­ and IPV. All 
our study participants reported good adherence during the 1­year 
study period, with non­adherence being assessed clinically if the 
tacrolimus C0 fell out of the therapeutic range.
Study limitations
The present study has several limitations. The fact that it was 
conducted at a single centre and had a relatively small sample size 
compared with other studies may affect some aspects of the findings, 
and translation of our results may not be feasible for other centres. 
The duration of follow­up (1 year) was short compared with other 
studies, where durations were up to 10 years, and longer follow­up 
may further describe the gene effect on creatinine over time. Other 
enzymes that may explain tacrolimus variability, such as CYP2C8, 
POR and the nuclear receptor PPAR­α, were not investigated owing 
to cost limitations. Linkage disequilibrium may be present among 
genes. Gene interactions may play an important role, and further 
study is needed to assess this effect.
Conclusions
This study confirms the previously described effects of CYP3A5 
SNPs on tacrolimus C0 and dosing requirements. Furthermore, 
it appears to support the notion that CYP3A5 non­expression 
may be associated with increased IPV in tacrolimus C0. With the 
exception of patients of mixed ancestry, black African and white 
ethnicity should serve as a proxy for CYP3A5 expression and non­
expression, respectively, in SA patients, necessitating higher and 
lower starting doses of tacrolimus, respectively, prior to therapeutic 
drug level monitoring being available. While a genotype­based 
tacrolimus dosing algorithm could still be beneficial in predicting 
an appropriate starting or switching dose of tacrolimus in a multi­
ethnic population such as ours, this could be restricted to patients 
of mixed ancestry in order to reduce costs. Finally, the high 
frequency of the CYP3A5*1/*1 and *1/*3 expressor genotype has 
important cost implications for the provision of tacrolimus­based 
immunosuppression in SA. Since tacrolimus is also used in the 
treatment of various autoimmune diseases, this may well have wider 
applicability outside of transplantation medicine.
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Figure 6. The effect of CYP3A5 genotype on tacrolimus IPV 
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Fig. 6. Effect of the CYP3A5 genotype on tacrolimus IPV. The median is 
shown by the dotted line. (CYP3A5 = cytochrome P-450 3A5 gene; IPV = 
intra-patient variability.)
Fig. 7. Tacrolimus IPV for the different ethnic groups studied. The median is 
shown by the dotted line. (IPV = intra-patient variability.)
 
 
Figure 7. IPV for different ethnic groups studied 
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